Since its inception, the MMRC has facilitated 19 Phase I and Phase II clinical trials. These trials include several combination approaches and novel compounds that are thought to be active against high-priority targets.

• Phase II Merck Zolinza-Velcade
• PRESS RELEASE
• Multiple Myeloma Research Consortium (MMRC) and Merck initiate Phase II Trial of Zolinza with Velcade in Relapsed and Refractory Multiple Myeloma Patients

• Phase II Wyeth Torisel-Velcade

• Phase I Elotuzumab-Revlimid-Dex

• Phase I Celgene Pomalidomide (CC-4047)
• PRESS RELEASE
• The Multiple Myeloma Research Consortium (MMRC) Partners with Celgene Corporation on Phase I/II Trial of Pomalidomide (CC-4047) in Relapsed and Refractory Multiple Myeloma Patients

• Phase I PDL Elotuzumab-Velcade-Dex
• PRESS RELEASE
• The Multiple Myeloma Research Consortium (MMRC) Announces the Initiation of Phase I/II Study of Elotuzumab (Huluc63) Monoclonal Antibody in Combination with Velcade

• Phase I RVDD (upfront)
• PRESS RELEASE
• The Multiple Myeloma Research Consortium (MMRC) Announces Initiation of First Four-Drug Combination Study to Treat Newly Diagnosed Multiple Myeloma Patients

• Phase Ib LBH859-Revlimid-Dex
• PRESS RELEASE
• Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor

• Phase Ib Novartis LBH589-Velcade
• ABSTRACT (ASH 2781)
• A Phase IB, Multicenter, Open-Label, Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma

• Phase I Semafore SF1126

• Phase II Proteolix Carfilzomib (relapsed)
• ABSTRACT (ASH 865)
• Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM)

• Phase II Proteolix Carfilzomib (relapsed/refractory)
• PRESS RELEASE
• The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
• ABSTRACT (ASH 864)
• Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM)

• Phase I Wyeth Torisel-Velcade
• PRESS RELEASE
• The Multiple Myeloma Research Consortium Commences Phase I/II Combination Study for the Treatment of Multiple Myeloma
• ABSTRACT (ASH 3696)
• Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma

• Phase I Ortho Tipifarnib-Velcade
• PRESS RELEASE
• Multiple Myeloma Research Consortium (MMRC), Emory University Commence Multi-Center Combination Study for the Treatment of Multiple Myeloma
• ABSTRACT (ASH 3706)
• A Phase I MMRC Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma

• Phase II Novartis LBH589
• PRESS RELEASE
• Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
• ABSTRACT (ASH 2774)
• A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma

• Phase I Trial of NPI-0052
• PRESS RELEASE
• The Multiple Myeloma Research Consortium and Nereus Pharmaceuticals Initiate Clinical Trial Investigating NPI-0052 to Treat Multiple Myeloma
• ABSTRACT (ASH 2270)
• Phase 1 Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma

• Phase I Keryx Perifosine-Revlimid-Dex
• PRESS RELEASE
• The Multiple Myeloma Research Consortium (MMRC) and Keryx Biopharmaceuticals Commence Multi-Center Combination Study for the Treatment of Multiple Myeloma
• ABSTRACT (ASH 3691)
• Phase I Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM)

• Phase I Novartis TKI258 (CHIR-258)
• PRESS RELEASE
• Chiron and the Multiple Myeloma Research Consortium Announce Initiation of Phase I Clinical Trial for CHIR-258
• ABSTRACT (MMRC Publications)
• Phase I trial of chir-258 in multiple myeloma